Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase NA 1Phase 4 1Phase 1/2 1

Status

Completed 4Withdrawn 3Terminated 3Recruiting 2Active not recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 72Breast Neoplasms 63Neoplasms 59Leukemia, Myeloid, Acute 59Multiple Myeloma 53Colorectal Neoplasms 48Lymphoma 46Recurrence 45Carcinoma, Hepatocellular 45Stomach Neoplasms 43Pancreatic Neoplasms 40Neoplasm Metastasis 39Prostatic Neoplasms 34Melanoma 34Leukemia 30Lymphoma, Non-Hodgkin 27Lymphoma, B-Cell 27Lung Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Glioblastoma 24Ovarian Neoplasms 23Lymphoma, Large B-Cell, Diffuse 21Esophageal Neoplasms 21Carcinoma, Renal Cell 20Myelodysplastic Syndromes 19Leukemia, Lymphocytic, Chronic, B-Cell 19Hematologic Neoplasms 19Colonic Neoplasms 19Head and Neck Neoplasms 18Lymphoma, Mantle-Cell 17

Interventions

trifluridine tipiracil drug combination 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Colorectal Cancer Metastatic × Clear all
NCT06379399 2024-04-23

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Zhejiang Cancer Hospital

Phase 1/2 Unknown
26 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡